![Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - The American Journal of Emergency Medicine Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - The American Journal of Emergency Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9a9ce991-748e-4fd8-b13d-8dca7228c4c6/gr1_lrg.jpg)
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - The American Journal of Emergency Medicine
![Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/acea3d1d-6e83-40e7-85e2-480d03fe22d5/imj14459-fig-0001-m.jpg)
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
![Table 1 from Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. | Semantic Scholar Table 1 from Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4f3852095221223b6e2ac1fdbc4d3a5fbbacb654/11-Table1-1.png)
Table 1 from Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. | Semantic Scholar
![Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/178d2226-ecf0-49db-bfbc-c79a774535a0/gr1.jpg)
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology
Clinical Effectiveness of Idarucizumab in Dabigatran Reversal | Wang | Journal of Cardiology and Therapy
![Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants - British Journal of Anaesthesia Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants - British Journal of Anaesthesia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/25670b81-20db-48b0-b594-b8feeeb3f4d0/gr1_lrg.jpg)
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants - British Journal of Anaesthesia
![These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015 These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=label-019705.jpg&id=591475)
These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015
![Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40119-020-00165-8/MediaObjects/40119_2020_165_Fig1_HTML.png)
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink
![Idarucizumab dosing in patients with excessive dabigatran body burden - British Journal of Anaesthesia Idarucizumab dosing in patients with excessive dabigatran body burden - British Journal of Anaesthesia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd5a9742-d203-4140-9244-7875564f8b99/gr1_lrg.jpg)